Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

Study:

A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma

Rationale:

Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Purpose:

This randomized phase III trial is studying combination chemotherapy in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Study Status: Recruiting

Recruiting:
Tanya M. Tekautz 866-223-8100

Condition Intervention Phase
Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)
Childhood Supratentorial Primitive Neuroectodermal Tumor
Ewing Sarcoma of Bone
Extraosseous Ewing Sarcoma
Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Peripheral Primitive Neuroectodermal Tumor of the Kidney
Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
Drug: vincristine sulfate
Drug: doxorubicin hydrochloride
Drug: cyclophosphamide
Drug: ifosfamide
Drug: etoposide
Drug: topotecan hydrochloride
Other: laboratory biomarker analysis
Phase 3

Verified by Children`s Oncology Group June, 2013

Sponsored by: Children`s Oncology Group
Information provided by: Children`s Oncology Group
ClinicalTrials.gov identifier: NCT01231906

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States

Mason Bond., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site